MAP2K1 and colorectal carcinoma: Expression of MAP2K1/MEK1 P124S and wild-type MAP2K1/MEK1 in the cetuximab sensitive CRC cell line DiFi showed that the mutation rescued ERK phosphorylation and confirmed it as a new driver of acquired cetuximab resistance (Figure 2).